{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:17Z","timestamp":1791550337506,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Control of major drug-modifiable risk factors for glycated hemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) remains unsatisfactory in the secondary prevention of coronary artery disease (CAD). We aimed to analyze patient knowledge and attainment of LDL-C, BP, and HbA1c treatment goals and associated factors in German CAD patients with and without diabetes mellitus (DM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Results<\/jats:title>\n            <jats:p>A total of 204 CAD patients (68\u2009\u00b1\u20098 years; 75.0% male; 84 with DM (41.2%)) completed a questionnaire assessing their knowledge of LDL-C (&lt;\u200955\u00a0mg\/dL), BP (age-adapted), and HbA1c (&lt;\u20097.0%) treatment goals and levels of information on predefined CAD topics as well as associated factors, including CAD duration, adherence to pharmacotherapy, and physician monitoring of secondary prevention. LDL-C, BP, and HbA1c were measured. The mean duration of CAD was 9.8\u2009\u00b1\u20098 years. A total of 98.5% reported good adherence to pharmacotherapy. Measurements of LDL-C (81.4%) and HbA1c (71.4%) were predominantly performed by general practitioners. LDL-C goals were attained significantly better in patients with DM (39.3% with vs. 16.7% without DM, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The attainment of BP goals did not differ between patients with and without DM (71.4% vs. 72.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.87). HbA1c goals were attained by 48.8% of DM patients. LDL-C goals were known by 6.0% of patients with vs. 9.2% without DM (<jats:italic>p<\/jats:italic>\u2009=\u20090.44), and BP goals were known by 36.9% with vs. 30.0% without DM (<jats:italic>p<\/jats:italic>\u2009=\u20090.36). Knowledge of HbA1c goals was prevalent in 53.6% of DM patients. Subjective levels of information on CAD topics did not differ between patients with and without DM. Logistic regression revealed that DM (odds ratio (OR) 3.73, 95% confidence interval (CI) 1.82\u20137.63) and knowledge of treatment goals were associated with LDL-C goal attainment (OR 3.84, CI 1.19\u201312.41); no such associations were identified for BP or HbA1c.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In German CAD patients with and without DM, a remarkable lack of knowledge and attainment of LDL-C treatment goals exists compared with BP and HbA1c. DM and knowledge of treatment goals were significantly associated with LDL-C treatment goal attainment. General practitioners rather than cardiologists or other specialties currently manage risk factor control.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>German Clinical Trials Register studyID DRKS00030703.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12872-025-04599-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:13:05Z","timestamp":1741162385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Associations of patient knowledge with drug-modifiable cardiovascular risk factor control in coronary artery disease patients with and without diabetes mellitus: results from the cross-sectional KNOW-ABC study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-0748","authenticated-orcid":false,"given":"Maximilian","family":"Brockmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Parco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris G.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Wies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Heinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Chernyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Icks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"6","key":"4599_CR1","doi-asserted-by":"publisher","first-page":"e005375","DOI":"10.1161\/CIRCOUTCOMES.118.005375","volume":"12","author":"AN Nowbar","year":"2019","unstructured":"Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005375.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"4599_CR2","doi-asserted-by":"crossref","unstructured":"Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R et al. Economic burden of cardiovascular diseases in the European union: a population-based cost study. Eur Heart J. 2023.","DOI":"10.1093\/eurheartj\/ehad583"},{"issue":"18","key":"4599_CR3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/eurjpc\/zwaa093","volume":"28","author":"SU Khan","year":"2022","unstructured":"Khan SU, Khan MU, Virani SS, Khan MS, Khan MZ, Rashid M, et al. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(18):2001\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"10285","key":"4599_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"TBPLTT Collaboration","year":"2021","unstructured":"Collaboration TBPLTT. Pharmacological blood pressure Lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.","journal-title":"Lancet"},{"issue":"5","key":"4599_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","volume":"8","author":"OR Ghosh-Swaby","year":"2020","unstructured":"Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4599_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"33","key":"4599_CR7","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology (ESC) and the European society of hypertension (ESH). Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"2","key":"4599_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"8","key":"4599_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryd\u00e9n L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824\u201335.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"4599_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, De Backer G, Ryd\u00e9n L, Jennings C, et al. EUROASPIRE IV: A European society of cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636\u201348.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"4599_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12961-020-00588-8","volume":"18","author":"VC Correa","year":"2020","unstructured":"Correa VC, Lugo-Agudelo LH, Aguirre-Acevedo DC, Contreras JAP, Borrero AMP, Pati\u00f1o-Lugo DF, et al. Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: a systematic metareview. Health Res Policy Syst. 2020;18(1):74.","journal-title":"Health Res Policy Syst"},{"issue":"34","key":"4599_CR12","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"2","key":"4599_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/clc.23948","volume":"46","author":"M Brockmeyer","year":"2023","unstructured":"Brockmeyer M, Wies E, Joerges J, Sommer J, Borgmann SO, Chernyak N, et al. Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(2):223\u201331.","journal-title":"Clin Cardiol"},{"issue":"4","key":"4599_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.pcd.2015.11.007","volume":"10","author":"N Chernyak","year":"2016","unstructured":"Chernyak N, Stephan A, B\u00e4chle C, Genz J, J\u00fclich F, Icks A. Assessment of information needs in diabetes: development and evaluation of a questionnaire. Prim Care Diabetes. 2016;10(4):287\u201392.","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"4599_CR15","first-page":"21","volume":"29","author":"LF Degner","year":"1997","unstructured":"Degner LF, Sloan JA, Venkatesh P. The control preferences scale. Can J Nurs Res. 1997;29(3):21\u201343.","journal-title":"Can J Nurs Res"},{"issue":"12","key":"4599_CR16","doi-asserted-by":"publisher","first-page":"e50537","DOI":"10.1371\/journal.pone.0050537","volume":"7","author":"JA Glombiewski","year":"2012","unstructured":"Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the general population. PLoS ONE. 2012;7(12):e50537.","journal-title":"PLoS ONE"},{"issue":"16","key":"4599_CR17","doi-asserted-by":"publisher","first-page":"e020893","DOI":"10.1161\/JAHA.120.020893","volume":"10","author":"SV Arnold","year":"2021","unstructured":"Arnold SV, Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, et al. What do US physicians and patients think about Lipid-Lowering therapy and goals of treatment?? Results from the GOULD registry. J Am Heart Assoc. 2021;10(16):e020893.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"4599_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1520-037X.2005.3939.x","volume":"8","author":"S Cheng","year":"2005","unstructured":"Cheng S, Lichtman JH, Amatruda JM, Smith GL, Mattera JA, Roumanis SA, et al. Knowledge of cholesterol levels and targets in patients with coronary artery disease. Prev Cardiol. 2005;8(1):11\u20137.","journal-title":"Prev Cardiol"},{"issue":"5","key":"4599_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.pcd.2017.03.011","volume":"11","author":"H Trivedi","year":"2017","unstructured":"Trivedi H, Gray LJ, Seidu S, Davies MJ, Charpentier G, Lindblad U, et al. Self-knowledge of HbA1c in people with type 2 diabetes mellitus and its association with glycaemic control. Prim Care Diabetes. 2017;11(5):414\u201320.","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"4599_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","volume":"147","author":"JS Hochman","year":"2023","unstructured":"Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O\u2019Brien SM, et al. Survival after invasive or Conservative management of stable coronary disease. Circulation. 2023;147(1):8\u201319.","journal-title":"Circulation"},{"issue":"15","key":"4599_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","volume":"387","author":"D Perera","year":"2022","unstructured":"Perera D, Clayton T, O\u2019Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387(15):1351\u201360.","journal-title":"N Engl J Med"},{"issue":"7","key":"4599_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/eurjpc\/zwad038","volume":"30","author":"TJ van Trier","year":"2023","unstructured":"van Trier TJ, Snaterse M, Hageman SHJ, Ter Hoeve N, Sunamura M, van Moll EP, et al. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2023;30(7):601\u201310.","journal-title":"Eur J Prev Cardiol"},{"key":"4599_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","volume":"14","author":"V Gyberg","year":"2015","unstructured":"Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the euroobservational research programme of the European society of cardiology. Cardiovasc Diabetol. 2015;14:133.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"4599_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"32","key":"4599_CR25","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"15","key":"4599_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid Lowering with Statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"25","key":"4599_CR27","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"15","key":"4599_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in Statin-Intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"18","key":"4599_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"4599_CR30","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"2","key":"4599_CR31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s12325-021-01985-3","volume":"39","author":"D Lautsch","year":"2022","unstructured":"Lautsch D, Boggs R, Wang T, Gonzalez C, Milligan G, Rajpathak S, et al. Individualized HbA(1c) goals, and patient awareness and attainment of goals in type 2 diabetes mellitus: A Real-World multinational survey. Adv Ther. 2022;39(2):1016\u201332.","journal-title":"Adv Ther"},{"key":"4599_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.zefq.2015.11.005","volume":"110\u2013111","author":"GPGI WG","year":"2016","unstructured":"GPGI WG. [Good practice guidelines for health information]. Z Evid Fortbild Qual Gesundhwes. 2016;110\u2013111:85\u201392.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"38","key":"4599_CR33","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940\u20138.","journal-title":"Eur Heart J"},{"issue":"4","key":"4599_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","volume":"5","author":"MJ Stirratt","year":"2015","unstructured":"Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470\u201382.","journal-title":"Transl Behav Med"},{"issue":"6","key":"4599_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/jhh.2015.103","volume":"30","author":"P Patel","year":"2016","unstructured":"Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368\u201373.","journal-title":"J Hum Hypertens"},{"key":"4599_CR36","doi-asserted-by":"crossref","unstructured":"Koenig W, Lorenz ES, Beier L, Gouni-Berthold I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2023.","DOI":"10.1007\/s00392-023-02257-6"},{"key":"4599_CR37","unstructured":"Nordrhein KV. Qualitaetsbericht 2023 Disease-Management-Programme 2024 [Available from: https:\/\/www.kvno.de\/fileadmin\/shared\/pdf\/print\/berichte\/dmp-berichte\/qualbe_dmp_23.pdf"},{"key":"4599_CR38","unstructured":"Federal-Joint-Committee. Beschluss des Gemeinsamen Bundesausschusses ueber die 18. \u00c4nderung der DMP-Anforderungen- Richtlinie (DMP-A-RL): Aenderung der Anlage 5 (DMP KHK) und Anlage 6 (KHK Dokumentation) 2019 [Available from: https:\/\/www.g-ba.de\/downloads\/39-261-4042\/2019-11-22_DMP-A-RL_Anlage-5-6-KHK_BAnz.pdf"},{"key":"4599_CR39","unstructured":"German-Medical-Association. Drug Commission: Neue europ\u00e4ische \u201eLeitlinie zur Lipidsenkung: As low as possible? 2020 [Available from: https:\/\/www.akdae.de\/fileadmin\/user_upload\/akdae\/Arzneimitteltherapie\/AVP\/Artikel\/2020-1-2\/021.pdf"},{"issue":"9","key":"4599_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of Lipid-Lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1\u20139.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"4599_CR41","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12325-022-02357-1","volume":"40","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Wolf M, Willfeld K, Beier L, Weing\u00e4rtner O. Different perspectives of patients and physicians on LDL-C target achievement in the treatment of hypercholesterolemia: results on secondary prevention from the German PROCYON survey. Adv Ther. 2023;40(2):460\u201373.","journal-title":"Adv Ther"},{"issue":"7","key":"4599_CR42","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.amjcard.2018.12.031","volume":"123","author":"A Lowenstern","year":"2019","unstructured":"Lowenstern A, Navar AM, Li S, Virani SS, Goldberg AC, Louie MJ, et al. Association of clinician knowledge and Statin beliefs with Statin therapy use and lipid levels (A survey of US practice in the PALM Registry). Am J Cardiol. 2019;123(7):1011\u20138.","journal-title":"Am J Cardiol"},{"issue":"6","key":"4599_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cjco.2020.07.002","volume":"2","author":"S Butalia","year":"2020","unstructured":"Butalia S, Lee-Krueger RCW, McBrien KA, Leung AAC, Anderson TJ, Quan H, et al. Barriers and facilitators to using Statins: A qualitative study with patients and family physicians. CJC Open. 2020;2(6):530\u20138.","journal-title":"CJC Open"},{"key":"4599_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-015-0037-y","volume":"14","author":"M Krempf","year":"2015","unstructured":"Krempf M, Simpson RJ Jr., Ramey DR, Brudi P, Giezek H, Tomassini JE, et al. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis. 2015;14:45.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"4599_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/clc.23935","volume":"46","author":"NR Desai","year":"2023","unstructured":"Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13\u201321.","journal-title":"Clin Cardiol"},{"issue":"2","key":"4599_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00392-022-02093-0","volume":"112","author":"K Ungeth\u00fcm","year":"2023","unstructured":"Ungeth\u00fcm K, Wiedmann S, Wagner M, Leyh R, Ertl G, Frantz S, et al. Secondary prevention in diabetic and nondiabetic coronary heart disease patients: insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys. Clin Res Cardiol. 2023;112(2):285\u201398.","journal-title":"Clin Res Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04599-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:13:11Z","timestamp":1741162391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04599-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4599"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04599-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was positively evaluated by the ethics committee of the Medical Faculty of Heinrich Heine University D\u00fcsseldorf (Study No. 2022\u2009\u2212\u20091907). All participants provided informed consent prior to study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was discussed with a patient who is a member of our cardiometabolic health services research group at HeinrichHeine University D\u00fcsseldorf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}